The Effects of a Selective CK2 Inhibitor on Anti-glomerular Basement Membrane Glomerulonephritis in Rats

DOI Web Site Web Site PubMed 22 References
  • Shi Junfeng
    Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Liu Ning
    Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Xiao Ying
    Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Takei Yoshinori
    Department of Nanobio Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Yasue Misato
    Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Suzuki Yamato
    Department of Bioorganic Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Hou Zengye
    Department of Bioorganic Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Ohno Hiroaki
    Department of Bioorganic Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Yamada Masateru
    Pharmaceutical Research Laboratories, Toray Industries Inc.
  • Fuchi Nobuhiro
    Pharmaceutical Research Laboratories, Toray Industries Inc.
  • Oshida Keiyu
    Pharmaceutical Research Laboratories, Toray Industries Inc.
  • Miyamoto Yohei
    Pharmaceutical Research Laboratories, Toray Industries Inc.
  • Tsujimoto Gozoh
    Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Hirasawa Akira
    Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University Institute for Integrated Medical Sciences, Tokyo Women’s Medical University

Search this article

Abstract

Protein kinase CK2 (“casein kinase II”) is a protein serine/threonine kinase that plays critical roles in biological processes such as cell growth, cell cycle progression, and apoptosis. So far, we have identified that one catalytic isozyme of CK2, CK2α, is over-expressed in the kidney during the progression of glomerulonephritis (GN). Moreover, we have shown that in vivo inhibition of CK2 by administration of CK2 inhibitors was effective in the treatment of experimental GN. Hence the development of potent CK2 inhibitors should be considered in therapeutic strategies for GN. In the present study we identified compound 13, a pyrazine derivative, as a potent CK2 inhibitor. By performing enzyme kinetics analysis in vitro, we characterized the inhibition of compound 13 toward each CK2 catalytic isozyme. Furthermore, in vivo, we demonstrated that compound 13 is effective in attenuating proteinuria, decreasing the enhanced level of blood urea nitrogen and serum creatinine, and ameliorating glomerular crescent formation in an experimental GN rat model. On the other hand, cellular apoptosis was detected in the rat testis following administration of compound 13. This study provides clues for new strategies for developing applicable compounds into CK2-targeted GN treatments.

Journal

References(22)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top